Spatial Neurolipidomics at the Single Amyloid-β Plaque Level in Postmortem Human Alzheimer's Disease Brain.

"The authors declare the following competing financial interest(s): HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work)."

"The authors thank the staff at Centre for Cellular Imaging (CCI), Core Facilities, The Sahlgrenska Academy, University of Gothenburg, and the National Microscopy Infrastructure, NMI (VR-RFI 2019-00022), for help with the development of imaging paradigm and microscopy expertise. W.M. is a SciLife DDLS fellow and receives financial support from the Swedish Research Council VR (#2021–00478). J.H. was supported by the Swedish Research Council VR (#2023–02796, #2018–02181, and #2019–02397), the Swedish Alzheimer Foundation (#AF-968238, #AF-939767, #AF- 980791) the National Institute of Health (NIH-NIA, R01AG078796, R21AG078538), Hjärnfonden (FO2022–0311), Magnus Bergvalls Stiftelse, and Åhlén-Stiftelsen (#213027). Stiftelsen Gamla Tjänarinnor, the Swedish Dementia Foundation (Demensfonden) and Gun och Bertil Stohnes Stiftelse. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2023–00356; #2022–01018, and #2019–02397), the European Union’s Horizon Europe research and innovation program under grant agreement no. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809–2016862), the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21–831376-C, #ADSF-21–831381-C, and #ADSF-21–831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022–0270), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 860197 (MIRIADE), the European Union Joint Programme–Neurodegenerative Disease Research (JPND2021–00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). K.B. was supported by the Swedish Research Council (#2017–00915 and #2022–00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, and #AF-968270), Hjärnfonden, Sweden (#FO2017–0243 and #ALZ2022–0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019–466–236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21–848495), the Alzheimer’s Association 2022–2025 Grant (SG-23–1038904 QC), and the Kirsten and Freddy Johansen Foundation."